Education
About Us
Working with TipRanks
Follow Us
Brainsway Ltd (BWAY)
NASDAQ:BWAY
BWAY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.06 - $15.94
Previous CloseN/A
Volume9.67K
Average Volume (3M)69.53K
Market Cap
$295.79M
Enterprise Value$176.35M
Total Cash (Recent Filing)$71.60M
Total Debt (Recent Filing)$5.57M
Price to Earnings (P/E)54.8
Beta1.48
Next Earnings
Nov 12, 2025EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding18,901,796
10 Day Avg. Volume112,755
30 Day Avg. Volume69,530
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue4.06
Enterprise Value/Gross Profit5.45
Enterprise Value/Ebitda29.02
Forecast
1Y Price Target
$17.50Price Target Upside14.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalsBrainsWay received expanded FDA labeling for Deep TMS to treat late-life depression, increasing the upper age limit from 68 to 86 years, thus broadening the availability of Deep TMS therapy.
Revenue PerformanceBrainsWay achieved record quarterly net revenue totaling $12.6M, essentially in line with forecasts.
Strategic InvestmentsAdditional strategic investments inked, setting the stage for accelerating revenue growth.
Bears Say
Expansion ChallengesRisks include slower-than-projected market uptake of Deep TMS systems, failure to expand reimbursement and market access, and inability to advance in other indications.
Market PenetrationRisks include slower-than-projected market uptake of Deep TMS systems and failure to expand reimbursement and market access.
Market RisksRisks include slower-than-projected uptake of Deep TMS systems, failure to expand reimbursement and market access, and possible long-term dilution risk.
Brainsway News
BWAY FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was $7.06 and its highest was $15.94 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is $295.79M.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is Nov 12, 2025 which is in 75 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on Aug 13, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.032 by $0.018.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Undervalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate is 0.05.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 18,901,796 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of $0.05 in its last earnings report, beating expectations of $0.032. Following the earnings report the stock price went up 4.184%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in BWAY
Brainsway Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.50 (14.68% Upside)
$17.50 (14.68% Upside)
Blogger Sentiment
Bullish
BWAY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 11.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.80%
12-Months-Change
Fundamentals
Return on Equity
9.70%
Trailing 12-Months
Asset Growth
69.99%
Trailing 12-Months
Company Description
Brainsway Ltd
Brainsway Ltd. is a medical technology company that specializes in developing and commercializing advanced non-invasive brain stimulation therapies. The company is primarily focused on treating various neuropsychiatric disorders, including major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), using its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology. Brainsway operates within the healthcare sector, leveraging innovative technology to provide solutions that improve patient outcomes and expand treatment options for mental health conditions.
BWAY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and strategic investments, alongside increased shipments and a solid recurring revenue model. Despite increased operating expenses and regulatory dependencies, the overall business outlook is positive with raised revenue guidance.View all BWAY earnings summariesBWAY Stock 12 Month Forecast
Average Price Target
$17.50
▲(14.68% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.86% Mutual Funds
23.81% Other Institutional Investors
75.22% Public Companies and
Individual Investors